MediciNova, Inc.
NASDAQ:MNOVBiotechnology
-$0.02 today
- Market cap
- $68.14M
- Beta
- 0.62
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.24
Volume 0.12M
Average 0.04M
MNOV EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
MediciNova, Inc.NASDAQ: MNOV
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$2.54M, compared with -$2.86M a year earlier. Trailing-twelve-month EBITDA was -$11.72M.
Context
- EBITDA amounted to 2922.4% of revenue in FY2025.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of -$10.78M (+9.9%) for the fiscal year ending Dec 2026, a step up from the -8.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$2.54M+10.9% QoQ
- Last fiscal yearDec 2025
- -$11.97M-8.6% YoY
- LTMMar 2026
- -$11.72M-5.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +11.1% | +4.7% | -6.4 pp |
| 1 year | -8.6% | +9.9% | +18.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (11.97M) USD
- Year-over-year change
- -8.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.97M) | -8.6% |
| FY2024 | 2024-12-31 | (11.02M) | -29.0% |
| FY2023 | 2023-12-31 | (8.55M) | +39.2% |
| FY2022 | 2022-12-31 | (14.05M) | -39.0% |
| FY2021 | 2021-12-31 | (10.11M) | — |
EBITDA vs competitors
How MNOV compares with its peers on the latest reported figures
- MNOV's LTM Mar 2026 EBITDA of -$11.72M is the 3rd highest of the 11 companies compared; the peer median is -$60.59M.
- Its year-over-year change of -5.2% is the 9th highest of 11, against a peer median of +2.7%.
- EBITDA amounts to 1963.7% of revenue for MNOV, versus a peer median of 761.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $148.02M | +264.5% | — | 223.7% | |
| LTM Mar 2026 | $47.3M | +203.4% | — | 18.5% | |
| LTM Mar 2026 | -$11.72M | -5.2% | — | 1963.7% | |
| LTM Mar 2026 | -$38.33M | -3.1% | — | — | |
| LTM Mar 2026 | -$46.12M | +63.6% | — | — | |
| LTM Mar 2026 | -$58.88M | -297.6% | — | — | |
CBUSCibus, Inc. | LTM Mar 2026 | -$62.31M | +76.4% | — | 1453.8% |
| LTM Mar 2026 | -$78.19M | +0.2% | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.08M | +0.7% | — | — |
| LTM Mar 2026 | -$104.13M | -8.2% | — | — | |
| LTM Mar 2026 | -$118.65M | +4.8% | — | 1298.7% | |
| Peer median (excluding MNOV) | -$60.59M | +2.7% | — | 761.2% | |
Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.04M | 0 | 1M | 0 | 409.66K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 378.61K |
| Gross Profit | 4.04M | 0 | 1M | 0 | 31.05K |
| Gross Margin | 100.0% | — | 100.0% | — | 7.6% |
| Research & Development | 8.1M | 9.14M | 5.66M | 7.2M | 7.15M |
| Selling, General & Admin | 5.72M | 5.48M | 5.24M | 5.48M | 6.16M |
| Operating Expenses | 14.25M | 14.63M | 10.9M | 12.68M | 13.31M |
| Depreciation & Amortization | 26.15K | 17.71K | 20.3K | 21.08K | 20.1K |
| EBITDA | (10.11M) | (14.05M) | (8.55M) | (11.02M) | (11.97M) |
| EBITDA Margin | -250.3% | — | -854.8% | — | -2922.4% |
| Operating Income | (10.22M) | (14.63M) | (9.9M) | (12.68M) | (13.28M) |
| Operating Margin | -253.0% | — | -990.0% | — | -3242.5% |
| Interest Income | 143.63K | 809.67K | 1.83M | 1.67M | 1.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 84.13K | 562.39K | 1.33M | 1.63M | 1.29M |
| Income Before Tax | (10.13M) | (14.07M) | (8.57M) | (11.04M) | (11.99M) |
| Pre-Tax Margin | -250.9% | — | -856.8% | — | -2927.3% |
| Income Tax Expense | 2.57K | 2.82K | 3.05K | 5.54K | 5.99K |
| Net Income | (10.13M) | (14.07M) | (8.57M) | (11.05M) | (12M) |
| Net Margin | -251.0% | — | -857.2% | — | -2928.8% |
| EPS (Basic) | (0.21) | (0.29) | (0.17) | (0.23) | (0.24) |
| EPS (Diluted) | (0.21) | (0.29) | (0.17) | (0.23) | (0.24) |
| Weighted Avg Shares | 48.6M | 49.05M | 49.05M | 49.05M | 49.06M |
| Weighted Avg Shares (Diluted) | 48.6M | 49.05M | 49.05M | 49.05M | 49.06M |
MediciNova, Inc.
NASDAQ:MNOV
Intrinsic Alpha fair value
Locked
Current Price
$1.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.